Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 9, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2025

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Sintilimab

200mg IV d1,Q3W

DRUG

Bevacizumab

7.5mg/kg IV d1,Q3W

COMBINATION_PRODUCT

Liver Protective Support Therapy

Medical treatment such as liver protection therapy, antiviral therapy, platelet and granulocyte upgrading therapy

Trial Locations (1)

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

All Listed Sponsors

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER